Opportunity for Celsius Holdings Investors: Join the Securities Fraud Class Action Lawsuit

Celsius Holdings Securities Fraud Class Action

Overview
Celsius Holdings, Inc. has recently become the focal point of a significant securities fraud lawsuit, reminding investors of their opportunity to take legal action. The Rosen Law Firm, known globally for its investor rights advocacy, is leading this initiative and notifying those who invested in common stock between February 29, 2024, and September 4, 2024.

Key Dates

The crucial deadline for potential lead plaintiffs is January 21, 2025. Those who purchased Celsius stock during the specified class period may be eligible to join the class action lawsuit without any upfront costs due to a unique contingency fee arrangement. This means investors could recover losses without paying out of pocket.

Actions to Take

To participate in the class action, interested investors are urged to visit Rosen Legal's website or contact Phillip Kim, Esq. directly at 866-767-3653 or via email at [email protected]. A lawsuit has already been initiated, and those wanting to act as lead plaintiff must submit their request to the court by the specified deadline.

Why Choose Rosen Law Firm?

Investors are encouraged to enlist the help of law firms with a solid track record in securities class actions. Rosen Law Firm not only has a history of successful class action litigations but also ranks among the top firms in terms of settlements achieved. Historically, they secured the largest securities class action settlement against a Chinese company, demonstrating their capability and commitment to investor rights.

The firm has been recognized for its robust performance, landing in the top four rankings for securities class action settlements annually since 2013. Their impressive record includes recovering hundreds of millions for investors, with over $438 million secured in 2019 alone. Furthermore, Laurence Rosen, a founding partner, received recognition as a prominent figure in the plaintiffs' bar.

Case Details

The lawsuit primarily centers around alleged misleading statements made by Celsius during the class period. Defendants are accused of failing to disclose critical information that led investors to believe Celsius was on a much stronger financial footing than it actually was. The allegations include:
1. Celsius overselling inventory to PepsiCo far beyond market demand, creating an unsustainable sales rate.
2. Significant reduction in future purchases from Pepsi, which would negatively impact Celsius’ sales and outlook.
3. That the company's financial performance metrics were, in fact, not nearly as robust as had been portrayed to investors.

These misrepresentations have caused financial harm to investors when the reality of the company's situation became apparent.

Joining the Class Action

Those wishing to join the Celsius Holdings class action can explore their options through the Rosen Law Firm’s dedicated resources. Potential plaintiff status provides the chance to be a representative voice in the case, guiding the litigation on behalf of other shareholders. However, until the class is officially certified, participants are not represented by counsel unless they expressly choose their own legal representation.

In addition, investors may opt to remain as absent class members and take no immediate action, though this choice could impact their ability to partake in any future recovery efforts.

Conclusion

Celsius Holdings investors should take swift action to protect their rights and interests. As the deadline looms, it’s crucial to engage qualified legal representation while considering the implications of joining the class action lawsuit. Stay informed on the latest developments by connecting with Rosen Law Firm through their social media platforms, enhancing your awareness of investor advocacy and rights.

For any inquiries or concerns, contact the ROSEN LAW FIRM, P.A. at 275 Madison Avenue, 40th Floor, New York, NY, or call 212-686-1060.

Disclaimer: Past results do not guarantee similar outcomes in future cases.